Table 1.
Characteristics of patients in the programme
| Characteristic | Category | Summary measure | Frequency | Proportion |
|---|---|---|---|---|
| Gender | Female | 920 | 43.4 | |
| Male | 1199 | 56.6 | ||
| Age | Range | 16–73 | ||
| Median | 35 (IQR: 30–41) | |||
| ≤24 | 106 | 5.0 | ||
| 25–39 | 1322 | 62.4 | ||
| 40–54 | 622 | 29.4 | ||
| ≥55 | 69 | 3.3 | ||
| Baseline CD4 count at registration | Median | 177 (IQR: I62–304) | ||
| <50 | 448 | 21.1 | ||
| 50–199 | 696 | 32.8 | ||
| 200–349 | 647 | 30.5 | ||
| 350–499 | 265 | 12.5 | ||
| >500 | 63 | 3.0 | ||
| Baseline WHO stage at registration | I | 305 | 14.4 | |
| II | 245 | 11.6 | ||
| III | 1318 | 62.2 | ||
| IV | 251 | 11.8 | ||
| TB diagnosis | Yes | 691 | 32.6 | |
| No | 1428 | 67.4 | ||
| Patients per GP | Median | 42 (IQR: 25–227) | ||
| <50 | 232 | 10.9 | ||
| 50–250 | 418 | 19.7 | ||
| >250 | 1469 | 69.3 | ||
| Months of follow-up | Median | 13 (IQR: 7–29) | ||
| ≤6 | 453 | 21.4 | ||
| 7–12 | 556 | 26.2 | ||
| 13–24 | 443 | 20.9 | ||
| 25–36 | 239 | 11.3 | ||
| 37–48 | 247 | 11.7 | ||
| 49–60 | 80 | 3.8 | ||
| 61–72 | 101 | 4.8 | ||
| ART status | Pre-ART (total) | 197 | 9.3 | |
| Ineligible | 32 | 1.5 | ||
| Eligible | 165 | 7.8 | ||
| On ART (total) | 1922 | 90.7 | ||
| Months on ART | Median | 14 (IQR: 8–30) | ||
| ≤6 | 357 | 18.6 | ||
| 7–12 | 525 | 27.3 | ||
| 13–24 | 433 | 22.5 | ||
| 25–36 | 216 | 11.2 | ||
| 37–48 | 234 | 12.2 | ||
| 49–60 | 75 | 3.9 | ||
| 61–72 | 82 | 4.3 | ||
| Status | Alive in programme | 1783 | 84.1 | |
| Lost to follow-up | 70 | 3.3 | ||
| Transferred out | 90 | 4.2 | ||
| Died | 176 | 8.3 |
ART, antiretroviral therapy; CD4, cluster of differentiation 4; GP, general practitioner; IQR, interquartile range; TB, tuberculosis; WHO, World Health Organization.